472 related articles for article (PubMed ID: 30068505)
1. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
3. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
5. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Morschhauser F; Ghosh N; Lossos IS; Palomba ML; Mehta A; Casasnovas O; Stevens D; Katakam S; Knapp A; Nielsen T; McCord R; Salles G
Blood Cancer J; 2021 Aug; 11(8):147. PubMed ID: 34417444
[TBL] [Abstract][Full Text] [Related]
7. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
[TBL] [Abstract][Full Text] [Related]
9. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Bachy E; Houot R; Feugier P; Bouabdallah K; Bouabdallah R; Virelizier EN; Maerevoet M; Fruchart C; Snauwaert S; Le Gouill S; Marolleau JP; Molina L; Moluçon-Chabrot C; Thieblemont C; Tilly H; Bijou F; Haioun C; Van den Neste E; Fabiani B; Meignan M; Cartron G; Salles G; Casasnovas O; Morschhauser F
Blood; 2022 Apr; 139(15):2338-2346. PubMed ID: 34936697
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot R; Cartron G; Bijou F; de Guibert S; Salles GA; Fruchart C; Bouabdallah K; Maerevoet M; Feugier P; Le Gouill S; Tilly H; Casasnovas RO; Moluçon-Chabrot C; Van Den Neste E; Zachee P; Andre M; Bonnet C; Haioun C; Van Hoof A; Van Eygen K; Molina L; Nicolas-Virelizier E; Ruminy P; Morschhauser F
Leukemia; 2019 Mar; 33(3):776-780. PubMed ID: 30291335
[No Abstract] [Full Text] [Related]
15. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J
Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Radford J; Davies A; Cartron G; Morschhauser F; Salles G; Marcus R; Wenger M; Lei G; Wassner-Fritsch E; Vitolo U
Blood; 2013 Aug; 122(7):1137-43. PubMed ID: 23843495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]